ASCO 2024: Immunotherapy for the Treatment of Small Cell Lung Cancer - Episode 11

Reviewing Ideate-Lung02: Durable Responses in Advanced SCLC

, , ,

Medical experts review the Ideate-Lung02 phase 3 clinical trial, exploring the potential for ifinatamab to elicit durable responses in patients with advanced small cell lung cancer (SCLC), and discussing the implications of these findings for the future treatment landscape of SCLC.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Optimizing First-Line Therapy for Limited-Stage Small Cell Lung Cancer
    EP. 2: ADRIATIC Trial: Durvalumab, cCRT Timing, and Survival in LS-SCLC
    EP. 3: cCRT-to-Durvalumab Interval in Limited Stage LS-SCLC
    EP. 4: Examining 3-Year Update Data from the CASPIAN Trial
    EP. 5: Predictors of Immunotherapy Response in Limited and Extensive SCLC
    EP. 6: Overcoming Immunotherapy Resistance in Small Cell Lung Cancer
    EP. 7: Examining the use of PD-L1 and tTMB in the CASPIAN Trial
    EP. 8: Redefining SCLC: Molecular Subtypes and Blood Biomarkers Guide Therapy
    EP. 9: Navigating Later-Line Therapy Sequencing in LS-SCLC Progression
    EP. 10: DELLphi-301: Platinum Chemotherapy Efficacy in SCLC Survival
    Now Viewing
    EP. 11: Reviewing Ideate-Lung02: Durable Responses in Advanced SCLC
    EP. 12: Examining Key Data from DAREON-8
    EP. 13: Closing Thoughts and Key Takeaways on Small Cell Lung Cancer

    Video content above is prompted by the following questions:

    1. B. Ideate-Lung02: Phase 3 Clinical Trial of Ifinatamab Deruxtecan vs TPC in Relapsed ES-SCL [TPS8126]
      1. Please share your perceptions of the potential for durable response to ifinatamab, a B7-H3-directed ADC in patients with previously treated, relapsed SCLC.
      2. How encouraging is an ORR of 52.4%, a 5.9-month median DoR, and a 12.2-month
      3. OS after a median 2 prior lines of therapy as reported in the Phase I/II trial?
      4. Currently, can you assay B7-H3 to determine individual expression levels?
      5. How does a treatment schedule of 12 mg/kg IV Q3W compare with that of:
      6. amrubicin [(Calsed) aminoanthracycline]: 45mg/m2 IV Infusion QD x 3 days Q3W [Japan]
      7. topotecan [(Hycamtin) topoisomerase inhibitor]: 1.5 mg/m2 IV infusion QD, Days 1-5 Q3W
      8. lurbinectedin [(Zepzelca) alkylating agent]: 3.2 mg/m2IV infusion Q3W
    2. What is the potential for immunogenicity with this ADC, and which treatment-related adverse events would most concern you?
    x